PJP ETF Explained: Returns, Expense Ratio, Holdings and Alternative ETFs
The Invesco Pharmaceuticals ETF (PJP) is a passive thematic product that invests in large US pharmaceutical companies that develop and sell new drugs. Its pharma-heavy structure is sensitive to drug pricing regulation, and differences in composition and weighting versus XPH, IHE and PPH are the key selection criteria.
What Is the Invesco Pharmaceuticals ETF?
This is a passive thematic ETF that tracks an index of large US pharmaceutical companies that develop and sell new drugs. By concentrating on the pharmaceutical industry, it gives exposure to new drug development and the earnings of pharmaceutical companies.
It suits investors who want concentrated exposure to the pharmaceutical sector and are willing to accept new drug development outcomes, drug pricing regulation, and sector concentration volatility.
It is a passive (index tracking) ETF managed by Invesco.
How Does the Invesco Pharmaceuticals ETF Invest?
| Item | Details |
|---|---|
| Investment Target | US pharmaceutical companies |
| Management Style | Passive (index tracking) |
| Theme | Pharmaceuticals |
| Dividend Frequency | Quarterly dividends |
| Expense Ratio | 0.58% |
It tracks an index of large US pharmaceutical companies that develop and sell new drugs. Using a weighting method that considers both momentum and fundamentals, it diversifies across pharmaceutical companies. It reflects the trends in new drug development and the pharmaceutical industry, but with a composition that differs from market-cap weighting.
- Focused on the US pharmaceutical industry
- Weighting that considers momentum and fundamentals
Invesco Pharmaceuticals ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) stand at $586.7M, and the Expense Ratio is 0.58% per year.
The main point of comparison is its narrower pharmaceutical-focused composition versus broad healthcare ETFs and biotech ETFs.
Invesco Pharmaceuticals ETF Performance and Trends
Pharmaceutical stocks are driven by clinical trial results, drug pricing regulation, mergers and acquisitions, and the interest rate environment. They tend to be strong when new drug successes and M&A expectations stand out, and weak when concerns over drug pricing regulation grow. Because the ETF centers on large pharmaceutical companies, its volatility tends to be somewhat lower than that of biotech.
Fund flows into pharmaceutical stocks split depending on new drug momentum, drug pricing policy, and demand for defensive characteristics. When concerns about an economic slowdown grow, money can also flow in for their defensive nature. It is also worth noting that performance varies with clinical trial results and the regulatory environment.
Invesco Pharmaceuticals ETF Pros and Cons
Its strengths are its pharmaceutical sector focus and defensive character, while drug pricing regulation, clinical trial risk, and sector concentration are points to consider.
💪 Key Strengths
⚠️ Points to Watch
Invesco Pharmaceuticals ETF Alternatives and Related Products
For equal-weighted exposure to pharmaceuticals, direct alternatives include XPH, and for other forms of pharmaceutical exposure, products such as IHE are also worth comparing. For a focus on global large-cap pharmaceuticals, products such as PPH can also be considered. This ETF's differentiators are its narrower exposure to the US pharmaceutical industry and a weighting that considers momentum and fundamentals.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| Vanguard Financials ETF | $131.80 | -1.9% | $12.9B | 0.09% | 1.78% | +6.0% | |
| Fidelity Nasdaq Composite Index ETF | $89.52 | -4.9% | $9.9B | 0.21% | 0.57% | +3.0% | |
| Vanguard Industrials ETF | $299.47 | -3.2% | $7.4B | 0.09% | 1.02% | +5.7% | |
| iShares U.S. Financials ETF | $126.18 | -2.1% | $3.7B | 0.37% | 1.54% | +4.6% | |
| First Trust Dorsey Wright Focus 5 ETF | $66.65 | -2.2% | $3.6B | 0.89% | 0.39% | +13.9% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| OmniAb Inc | - | $4.66 | -7.4% | $679.7M | - | - | |
| ABT | Abbott Laboratories | 0.06% | $103.00 | -0.8% | $178.4B | 38.0 | 2.53% |
| ABBV | Abbvie Inc | 0.05% | $286.20 | +0.9% | $505.9B | 49.3 | 2.4% |
| AMGN | AMGEN Inc | 0.05% | $435.64 | -0.7% | $235.6B | 25.3 | 2.31% |
| PFE | Pfizer Inc | 0.05% | $27.40 | -0.5% | $156.2B | 39.2 | 6.28% |
| JNJ | Johnson & Johnson | 0.05% | $270.47 | +1.3% | $651.1B | 41.0 | 1.97% |
| MRK | Merck & Co Inc | 0.05% | $133.72 | +0.7% | $329.7B | 136.6 | 2.55% |
Invesco Pharmaceuticals ETF Investor Checkpoints
Here are the points to review before investing in PJP. Its pharmaceutical sector focus and defensive character are appealing, but drug pricing regulation, clinical trial risk, and sector concentration should be checked in advance. It is also advisable to compare it with broad healthcare and biotech products.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💊 Pharmaceutical Exposure | Review the composition of large pharmaceutical companies | Pharma-focused |
| ⚖️ Drug Pricing Regulation | Review drug price cut policies | Needs checking |
| ⚗️ Clinical Trials and Patents | Review new drug trials and patent expirations | Needs checking |
| 🏥 Defensive Character | Review demand for essential medicines | Relatively resilient |
Drug price cut regulations, failed clinical trials for new drugs, and patent expirations are the main variables for short-term performance, and because the ETF is concentrated in a single pharmaceutical theme, it is sensitive to regulatory and clinical news. Given its sector concentration, it can also fall along with the market during periods of weakness.
It is a suitable candidate for investors who want concentrated exposure to the pharmaceutical sector. If you want equal-weighted pharmaceuticals or a different form of pharmaceutical exposure, compare products such as XPH and IHE, and if you want a pharmaceutical focus, compare this product alongside them before choosing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 10, 2026.